Search Results

You searched for : inflammasome

	Zydus announces Phase I trials of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor Zydus, today announced that it has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.... Dec 07
	Zydus announces IND filing of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor NLRP3 inflammasome inhibitor can selectively modulate the inflammatory responses caused by the â€˜Cytokine Stormâ€™ in Acute Respiratory Distress Syndrome... Nov 03
	HUYA Bioscience announces orphan drug Designation for HBI-8000 in Japan HBI-8000 for Monotherapy Adult T-cell Leukemia-Lymphoma ATL ... Oct 01
	Scientists Identify Immune System Variation Linked To Severe COVID-19 Cases The researchers from Yale University in the US examined 113 patients admitted to the Yale New Haven Hospital... Aug 13
	Scientists identify immune system variation linked to severe COVID-19 The researchers from Yale University in the US examined 113 patients admitted to the Yale New Haven Hospital... Jul 28
	Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
6 Matching result(s) found!

-Advertisements-

Trending Now
	Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
	International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
	The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
	Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
	Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
	In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
	Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
	Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
	10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
	Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
	The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
	Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
	A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
	The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
	ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
	The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
	Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
	Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
	AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
	Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024

Search Results

Zydus announces Phase I trials of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor

Zydus announces IND filing of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor

HUYA Bioscience announces orphan drug Designation for HBI-8000 in Japan

Scientists Identify Immune System Variation Linked To Severe COVID-19 Cases

Scientists identify immune system variation linked to severe COVID-19

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Trending Now